Changes in Trends and Pattern of Strong Opioid Prescribing in Primary Care

Overview

Journal Eur J Pain

Publisher Wiley

Specialties Critical Care
Neurology
Psychiatry

Date 2014 Apr 24

PMID 24756859

Citations 103

Authors

C S Zin

L C Chen

R D Knaggs

Affiliations

Soon will be listed here.

Abstract

Background: This study evaluated the prescribing trends of four commonly prescribed strong opioids in primary care and explored utilization in non-cancer and cancer users.

Methods: This cross-sectional study was conducted from 2000 to 2010 using the UK Clinical Practice Research Datalink. Prescriptions of buprenorphine, fentanyl, morphine and oxycodone issued to adult patients were included in this study. Opioid prescriptions issued after patients had cancer medical codes were defined as cancer-related use; otherwise, they were considered non-cancer use. Annual number of prescriptions and patients, defined daily dose (DDD/1000 inhabitants/day) and oral morphine equivalent (OMEQ) dose were measured in repeat cross-sectional estimates.

Results: In total, there were 2,672,022 prescriptions (87.8% for non-cancer) of strong opioids for 178,692 users (59.9% female, 83.9% non-cancer, mean age 67.1 ± 17.0 years) during the study period. The mean annual (DDD/1000 inhabitants/day) was higher in the non-cancer group than in the cancer group for all four opioids; morphine (0.73 ± 0.28 vs. 0.12 ± 0.04), fentanyl (0.46 ± 0.29 vs. 0.06 ± 0.24), oxycodone (0.24 ± 0.19 vs. 0.038 ± 0.028) and buprenorphine (0.23 ± 0.15 vs. 0.008 ± 0.006). The highest proportion of patients were prescribed low opioid doses (OMEQ ≤ 50 mg/day) in both non-cancer (50.3%) and cancer (39.9%) groups, followed by the dose ranks of 51-100 mg/day (26.2% vs. 28.7%), 101-200 mg/day (15.1% vs. 19.2%) and >200 mg/day (8.25% vs. 12.1%).

Conclusions: There has been a huge increase in strong opioid prescribing in the United Kingdom, with the majority of prescriptions for non-cancer pain. Morphine was the most frequently prescribed, but the utilization of oxycodone, buprenorphine and fentanyl increased markedly over time.

Citing Articles

Opioid Utilisation in Hungary: National and Regional Analysis in Ambulatory and Hospital Care Sector.

Dewi N, Matuz M, Szok D, Engi Z, Soos G, Csenki M J Clin Med. 2025; 14(3).

PMID: 39941568 PMC: 11818432. DOI: 10.3390/jcm14030897.

Impact of adverse childhood experiences on analgesia-related outcomes: a systematic review.

Senaratne D, Koponen M, Barnett K, Smith B, Hales T, Marryat L Br J Anaesth. 2024; 134(2):461-491.

PMID: 39438213 PMC: 11775844. DOI: 10.1016/j.bja.2024.09.015.

Exceeding the guideline-recommended maximum daily dose of opioids for long-term treatment of non-cancer pain in Germany - a large retrospective observational study.

Schrader N, Niemann A, Weitzel M, Speckemeier C, Abels C, Blase N BMC Public Health. 2024; 24(1):2580.

PMID: 39334000 PMC: 11429179. DOI: 10.1186/s12889-024-20141-4.

Use and misuse of psychoactive medicines: a descriptive cross-sectional study in a densely populated region of Portugal.

Araujo A, Guerreiro J, Bulhosa C, Alves da Costa F, Goulao J, Martins A J Pharm Policy Pract. 2024; 17(1):2369319.

PMID: 39081707 PMC: 11288207. DOI: 10.1080/20523211.2024.2369319.

Opioid exit plans for tapering postoperative pain control in noncancer patients: a systematic review.

Rainer M, Ommerli S, Burden A, Betschart L, Stampfli D Patient Saf Surg. 2024; 18(1):25.

PMID: 39080780 PMC: 11290124. DOI: 10.1186/s13037-024-00408-w.

References

Hamunen K, Paakkari P, Kalso E . Trends in opioid consumption in the Nordic countries 2002-2006. Eur J Pain. 2008; 13(9):954-62. DOI: 10.1016/j.ejpain.2008.11.006. View

Caudill-Slosberg M, Schwartz L, Woloshin S . Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain. 2004; 109(3):514-519. DOI: 10.1016/j.pain.2004.03.006. View

Fredheim O, Skurtveit S, Breivik H, Borchgrevink P . Increasing use of opioids from 2004 to 2007 - pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain. 2009; 14(3):289-94. DOI: 10.1016/j.ejpain.2009.05.006. View

Scholten W, Nygren-Krug H, Zucker H . The World Health Organization paves the way for action to free people from the shackles of pain. Anesth Analg. 2007; 105(1):1-4. DOI: 10.1213/01.ane.0000267542.72315.34. View

Unruh A . Gender variations in clinical pain experience. Pain. 1996; 65(2-3):123-67. DOI: 10.1016/0304-3959(95)00214-6. View

Svendsen K, Borchgrevink P, Fredheim O, Hamunen K, Mellbye A, Dale O . Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med. 2011; 25(7):725-32. DOI: 10.1177/0269216311398300. View

Zerzan J, Morden N, Soumerai S, Ross-Degnan D, Roughead E, Zhang F . Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002. Med Care. 2006; 44(11):1005-10. DOI: 10.1097/01.mlr.0000228025.04535.25. View

Ponizovsky A, Pchelintsev M, Marom E, Zvartau E . Differences in the consumption rates and regulatory barriers to the accessibility of strong opioid analgesics in Israel and St. Petersburg. Eur J Clin Pharmacol. 2011; 68(1):89-95. DOI: 10.1007/s00228-011-1099-z. View

Dunn K, Saunders K, Rutter C, Banta-Green C, Merrill J, Sullivan M . Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010; 152(2):85-92. PMC: 3000551. DOI: 10.7326/0003-4819-152-2-201001190-00006. View

10.

Portenoy R . Appropriate use of opioids for persistent non-cancer pain. Lancet. 2004; 364(9436):739-40. DOI: 10.1016/S0140-6736(04)16951-1. View

11.

Richard Chapman C, Lipschitz D, Angst M, Chou R, Denisco R, Donaldson G . Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base. J Pain. 2010; 11(9):807-29. DOI: 10.1016/j.jpain.2010.02.019. View

12.

Kelly J, Cook S, Kaufman D, Anderson T, Rosenberg L, Mitchell A . Prevalence and characteristics of opioid use in the US adult population. Pain. 2008; 138(3):507-513. DOI: 10.1016/j.pain.2008.01.027. View

13.

Boggon R, van Staa T, Chapman M, Gallagher A, Hammad T, Richards M . Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiol Drug Saf. 2012; 22(2):168-75. DOI: 10.1002/pds.3374. View

14.

Sullivan M, Ferrell B . Ethical challenges in the management of chronic nonmalignant pain: negotiating through the cloud of doubt. J Pain. 2005; 6(1):2-9. DOI: 10.1016/j.jpain.2004.10.006. View

15.

Okie S . A flood of opioids, a rising tide of deaths. N Engl J Med. 2010; 363(21):1981-5. DOI: 10.1056/NEJMp1011512. View

16.

Lawrenson R, Williams T, Farmer R . Clinical information for research; the use of general practice databases. J Public Health Med. 1999; 21(3):299-304. DOI: 10.1093/pubmed/21.3.299. View

17.

Hurley R, Adams M . Sex, gender, and pain: an overview of a complex field. Anesth Analg. 2008; 107(1):309-17. PMC: 2715547. DOI: 10.1213/01.ane.0b013e31816ba437. View

18.

Higginson I, Gao W . Opioid prescribing for cancer pain during the last 3 months of life: associated factors and 9-year trends in a nationwide United Kingdom cohort study. J Clin Oncol. 2012; 30(35):4373-9. DOI: 10.1200/JCO.2012.42.0919. View

19.

Williams T, van Staa T, Puri S, Eaton S . Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf. 2014; 3(2):89-99. PMC: 4110844. DOI: 10.1177/2042098611435911. View

20.

Sullivan M, Edlund M, Fan M, DeVries A, Brennan Braden J, Martin B . Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008; 138(2):440-449. PMC: 2668925. DOI: 10.1016/j.pain.2008.04.027. View